• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Rolfe Lindsey converted options into 5,063 shares and sold $3,054 worth of shares (2,545 units at $1.20), increasing direct ownership by 2% to 109,578 units to satisfy withholding tax

    9/6/22 4:15:35 PM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLVS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Rolfe Lindsey

    (Last) (First) (Middle)
    C/O CLOVIS ONCOLOGY, INC.
    5500 FLATIRON PARKWAY, SUITE 100

    (Street)
    BOULDER CO 80301

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Clovis Oncology, Inc. [ CLVS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    09/01/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 09/01/2022 M 5,063 A (1) 112,123 D
    Common Stock 09/02/2022 S 2,545(2) D $1.2 109,578 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 09/01/2022 M 5,063 (3) (3) Common Stock 5,063 $0.00 50,625 D
    Explanation of Responses:
    1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
    2. Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
    3. On March 1, 2021, the reporting person was granted 81,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2022, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date
    Remarks:
    Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance
    /s/ Lindsey Rolfe 09/02/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLVS

    DatePrice TargetRatingAnalyst
    5/6/2022Buy → Neutral
    H.C. Wainwright
    9/21/2021$10.00 → $9.00Buy
    HC Wainwright & Co.
    8/5/2021$12.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Rolfe Lindsey converted options into 8,374 shares and sold $4,188 worth of shares (4,261 units at $0.98), increasing direct ownership by 4% to 113,691 units (tax withholding)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:14 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gross Paul Edward converted options into 10,248 shares and sold $4,649 worth of shares (4,730 units at $0.98), increasing direct ownership by 6% to 98,330 units (for tax liability)

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:43 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Ivers-Read Gillian C converted options into 8,374 shares and sold $3,618 worth of shares (3,681 units at $0.98), increasing direct ownership by 2% to 293,612 units to satisfy withholding obligation

      4 - Clovis Oncology, Inc. (0001466301) (Issuer)

      11/3/22 4:15:37 PM ET
      $CLVS
      Biotechnology: Pharmaceutical Preparations
      Health Care